Eli Lilly 2011 Annual Report Download - page 2

Year in Review
1 Financial Highlights
2 Letter to Shareholders
6 Transforming Challenges into Advances: Lilly People in Action
9 Pipeline of Molecules in Clinical Development
Form 10-K
2 Products
17 Results of Operations
31 Consolidated Statements of Operations
32 Consolidated Statements of Comprehensive Income
33 Consolidated Balance Sheets
34 Consolidated Statements of Cash Flows
35 Segment Information
36 Selected Quarterly Data
37 Selected Financial Data
39 Notes to Consolidated Financial Statements
66 Management’s Reports
67 Reports of Independent Registered Public Accounting Firm
For more information on Lilly’s commitment to corporate
responsibility, please see the inside back cover of this report.
The Lilly Promise
Our Mission
Lilly makes medicines that help people live longer,
healthier, more active lives.
Our Values
Integrity | Excellence | Respect for People
We promise to operate our business with absolute
integrity and earn the trust of all, set the highest
standards for our performance and for the performance
of our products, and demonstrate caring and respect
for all those who share in our mission and are touched
by our work.
Our Vision
We will make a signifi cant contribution to humanity by
improving global health in the 21st century. Starting
with the work of our scientists, we will place improved
outcomes for individual patients at the center of what
we do. We will listen carefully to understand patient
needs and work with health care partners to provide
meaningful benefi ts for the people who depend on us.
Our Strategy
We will create value for all our stakeholders by accel-
erating the fl ow of innovative medicines that provide
improved outcomes for individual patients.
Transforming
As we enter 2012, Eli Lilly and Company comes face to
face with the most challenging period in its 135-year
history. A series of patent expirations for some of our
largest products place downward pressure on our rev-
enue at a time when we must invest to deliver the full
promise of our pipeline, including 12 molecules—the
most ever—in Phase III testing.
Yet we remain confi dent in our time-tested ability to
transform this signifi cant challenge into advances—
new medicines that will push forward the frontiers of
science and provide hope, healing, and health to the
millions of people who depend on us.
The foundation of our success, as always, will be our
talented Lilly associates, whose dedication and com-
mitment to our important mission have never wavered.
Working with partners around the world, we will forge
ahead in our quest to fi nd solutions for some of our
most vexing health care challenges, including cancer,
Alzheimer’s disease, diabetes, and mental illness.
Transforming challenges into advances: This is the
subtitle of our company’s proud history. We’re doing it
still today. We’ll be doing it tomorrow.
Proxy Statement
1 Notice of 2012 Annual Meeting and Proxy Statement
2 Proxy Statement Overview
4 Board of Directors
11 Highlights of the Company’s Corporate Governance Guidelines
16 Committees of the Board of Directors
17 Membership and Meetings of the Board and Its Committees
18 Director Compensation
20 Directors and Corporate Governance Committee Matters
21 Audit Committee Matters
23 Compensation Committee Matters
25 Compensation Discussion and Analysis
39 Executive Compensation
39 Summary Compensation Table
49 Ownership of Company Stock
51 Items of Business To Be Acted Upon at the Meeting
57 Meeting and Voting Logistics
60 Other Matters
61 Appendix A
Corporate Information
1 Executive Committee and Senior Leadership
2 Corporate Information
5 Annual Meeting Admission Ticket